Inhibition of the Wnt pathway may be efficacious in triple negative breast cancers overexpressing R-spondins35, a therapeutic relationship that should be explored in HGSOC demonstrating the PLCB1 fusion or high R-spondin levels for other mechanistic reasons. This evidence concerns the gene RSPO1 and triple-negative breast carcinoma.